Amylyx Pharmaceuticals (AMLX) Shares Outstanding (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Shares Outstanding (Entity) of $111.0 million for Q1 2026, up 24.64% year-over-year from $89.1 million in Q1 2025, and up 1.04% quarter-over-quarter from $109.9 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Shares Outstanding (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Shares Outstanding (Entity) history runs 6 years deep, the most recent figure standing at $111.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 24.64% year-over-year to $111.0 million; the TTM figure through Mar 2026 stood at $111.0 million (up 24.64% YoY), while the FY2025 annual figure was $109.9 million, up 60.11% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $111.0 million, up from $109.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $111.0 million in Q1 2026, with the low at $57.9 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $68.0 million (2024), against an average of $76.1 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) soared 847.4% in 2022, then grew 1.08% in 2024.
- Amylyx Pharmaceuticals' Shares Outstanding (Entity) stood at $66.5 million in 2022, then gained by 1.8% to $67.7 million in 2023, then rose by 1.36% to $68.6 million in 2024, then surged by 60.11% to $109.9 million in 2025, then increased by 1.04% to $111.0 million in 2026.
- Business Quant data shows AMLX's Shares Outstanding (Entity) at $111.0 million in Q1 2026, $109.9 million in Q4 2025, and $109.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | 8.89 Bn |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 1.08 Bn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 499.50 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | 111.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.20 Mn |
| Mar 31, 2026 | 110.56 Mn |
| Dec 31, 2025 | 94.57 Mn |
| Sep 30, 2025 | 93.33 Mn |
| Jun 30, 2025 | 89.14 Mn |
| Mar 31, 2025 | 85.70 Mn |
| Dec 31, 2024 | 68.14 Mn |
| Sep 30, 2024 | 68.09 Mn |
| Jun 30, 2024 | 68.02 Mn |
| Mar 31, 2024 | 67.85 Mn |
| Dec 31, 2023 | 67.23 Mn |
| Sep 30, 2023 | 67.41 Mn |
| Jun 30, 2023 | 67.23 Mn |
| Mar 31, 2023 | 66.72 Mn |
| Dec 31, 2022 | 58.50 Mn |
| Sep 30, 2022 | 58.53 Mn |
| Jun 30, 2022 | 58.28 Mn |
| Mar 31, 2022 | 51.60 Mn |
| Dec 31, 2021 | 6.59 Mn |
| Sep 30, 2021 | 6.76 Mn |